Ticker > Company >

Genpharmasec share price

Genpharmasec Ltd.

BSE: 531592 SECTOR: Dyes & Pigments  40k   156   20

3.18
-0.08 (-2.45%)
BSE: Today, 04:01 PM

Price Summary

Today's High

₹ 3.3

Today's Low

₹ 3.15

52 Week High

₹ 7.31

52 Week Low

₹ 1.92

FinStar

Ownership Below Par
Stock price may face volatility due to ownership structure.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyPoor
The company seems highly inefficient in case of asset management.
FinancialsWeak
Watch out! The company might not be able to sustain any adverse condition.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

176.08 Cr.

Enterprise Value

160.71 Cr.

No. of Shares

55.37 Cr.

P/E

110.42

P/B

2.66

Face Value

₹ 1

Div. Yield

0 %

Book Value (TTM)

₹  1.2

CASH

18.58 Cr.

DEBT

3.21 Cr.

Promoter Holding

29.98 %

EPS (TTM)

₹  0.03

Sales Growth

19.16%

ROE

0.12 %

ROCE

2%

Profit Growth

-95.89 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year19.16%
3 Year12.58%
5 Year140.85%

Profit Growth

1 Year-95.89%
3 Year-66.76%
5 Year-27.52%

ROE%

1 Year0.12%
3 Year2.02%
5 Year3.84%

ROCE %

1 Year2%
3 Year0.51%
5 Year3.01%

Debt/Equity

0.0497

Price to Cash Flow

-77.45

Interest Cover Ratio

2.1822

CFO/PAT (5 Yr. Avg.)

0

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Sep 2024 29.98 0.00
Jun 2024 29.98 0.00
Mar 2024 29.98 0.00
Dec 2023 59.96 0.00
Sep 2023 59.96 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • Company is virtually debt free.
  • Company has a healthy liquidity position with current ratio of 14.8476.

 Limitations

  • The company has shown a poor profit growth of -66.7552677260073% for the Past 3 years.
  • The company has shown a poor revenue growth of 12.5832171909231% for the Past 3 years.
  • Company has a poor ROE of 2.01625011055169% over the past 3 years.
  • Company has a poor ROCE of 0.51258831013122% over the past 3 years
  • Company has negative cash flow from operations of -2.2736.
  • The company has a low EBITDA margin of 1.83091917099287% over the past 5 years.
  • The company is trading at a high PE of 110.42.
  • The company is trading at a high EV/EBITDA of 68.7307.

Quarterly Result (All Figures in Cr.)

PARTICULARS Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024
Net Sales 7.86 6.39 10.2 5.3 5.77
Total Expenditure 7.9 6.37 10.04 5.07 5.51
Operating Profit -0.04 0.02 0.16 0.23 0.26
Other Income 0.15 0.14 0.31 0.58 0.86
Interest 0.07 0.13 0.14 0.07 0.04
Depreciation 0 0.01 0 0.01 0.04
Exceptional Items 0 0 0 0 0
Profit Before Tax 0.04 0.03 0.33 0.73 1.03
Tax 0.04 -0.03 0.38 0.14 0.03
Profit After Tax 0.01 0.06 -0.05 0.59 1
Adjusted EPS (Rs) 0 0 0 0.01 0.02

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Net Sales 16.5 21.31 27.32 25.52 30.41
Total Expenditure 15.85 20.11 27.84 25.26 30.25
Operating Profit 0.65 1.19 -0.52 0.26 0.16
Other Income 0.56 0.33 0.09 0.1 0.72
Interest 0 0 0 0.06 0.39
Depreciation 0 0.01 0.01 0.02 0.02
Exceptional Items 0 0 0 0 0
Profit Before Tax 1.21 1.51 -0.44 0.28 0.47
Tax 0.2 0.25 -0.23 -0.84 0.42
Net Profit 1.01 1.26 -0.21 1.12 0.05
Adjusted EPS (Rs.) 0.03 0.03 0 0.02 0

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity and Liabilities
Share Capital 21.69 21.69 27.69 27.69 55.37
Total Reserves -2.65 -1.02 -12.32 -12.36 9.2
Borrowings 0 0 0 2.48 3.21
Other N/C liabilities 0 0 0 -0.85 -0.43
Current liabilities 5.72 7.16 6.28 2.06 2.7
Total Liabilities 24.75 27.82 21.65 19.03 70.05
Assets
Net Block 0.05 0.05 0.1 0.1 0.1
Capital WIP 0 0 0 0 0
Intangible WIP 0 0 0 0 0
Investments 3.48 0.14 0 0 17.84
Loans & Advances 5.34 0.85 0 0 12.07
Other N/C Assets 0 0 0 0 0
Current Assets 15.88 26.78 21.54 18.93 40.04
Total Assets 24.75 27.82 21.65 19.03 70.05
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Profit from operations 1.21 1.51 -0.44 0.28 0.47
Adjustment -0.54 -0.31 -0.04 0.16 0.29
Changes in Assets & Liabilities 0.78 -2.98 -1.83 -3.77 -2.99
Tax Paid -0.05 -0.35 -0.03 0.26 -0.04
Operating Cash Flow 1.39 -2.13 -2.34 -3.06 -2.27
Investing Cash Flow -4.01 -1.41 0.42 0.36 -29.03
Financing Cash Flow 0 4.5 0 3.08 47.89
Net Cash Flow -2.62 0.96 -1.93 0.39 16.59

Corporate Actions

Investors Details

PARTICULARS Sep 2023% Dec 2023% Mar 2024% Jun 2024% Sep 2024%
promoters 59.96 59.96 29.98 29.98 29.98
rajesh sadhwani 26.37 26.37 13.18 13.18 13.18
sneha sadhwani 33.59 33.59 16.80 16.80 16.80
PARTICULARS Sep 2023% Dec 2023% Mar 2024% Jun 2024% Sep 2024%
investors 40.04 40.04 70.02 70.02 70.02
anant wealth consultants - - - - 1.24
divya deven pathak - - 1.99 1.99 1.99
narendra chhaganlal solan... - - 1.09 1.09 1.09
ramesh sakharampant deshp... - - 1.08 1.08 1.08
rashmi nimesh joshi 1.28 1.28 1.28 1.28 1.28
sadashiv kanyana shetty - - 1.80 1.80 2.06
stallion wealth managemen... - - - - 1.09
vishesh mahesh nihalani - - 1.52 1.52 1.53
yogeshkumar rasiklal sang... - - 7.82 7.82 7.08
mansi share & stock advis... - - 2.71 - -
multiplier share & stock ... - - 2.40 - -
jigney bhachech huf 1.44 1.44 - - -
manish ravilal patel huf 1.09 1.09 - - -
dinesh ravilal patel huf 1.03 - - - -
mitul ravilal patel huf 1.42 - - - -

Ratings & Research Reports

No Credit and Research reports exist for this company.Report us

Company Presentations

Currently we do not have any Presentation and Concall related to this company.Report us

Company News

Genpharmasec enters into Supper stockist agreement with Amneal Healthcare 10 Dec, 2:57 PM Genpharmasec informs about press release 10 Dec, 1:24 PM Genpharmasec - Quaterly Results 12 Nov, 4:51 PM Genpharmasec informs about RTA certificate 8 Oct, 2:58 PM Genpharmasec - Quaterly Results 13 Aug, 6:01 PM Genpharmasec - Quaterly Results 13 Aug, 6:01 PM Genpharmasec - Quaterly Results 24 May, 11:35 PM Genpharmasec - Quaterly Results 24 May, 11:35 PM Genpharmasec informs about board meeting 14 May, 5:11 PM Genpharmasec informs about board meeting 21 Mar, 4:48 PM Genpharmasec acquires 70% stake in Derren Healthcare 11 Mar, 5:52 PM Genpharmasec informs about updates on acquisition 11 Mar, 4:27 PM Genpharmasec - Quaterly Results 12 Feb, 5:02 PM Genpharmasec - Quaterly Results 12 Feb, 5:02 PM Genpharmasec - Quaterly Results 12 Feb, 5:02 PM Genpharmasec forms wholly owned subsidiary 29 Jan, 4:47 PM Genpharmasec informs about newspaper advertisement 22 Jan, 4:54 PM Genpharmasec informs about outcome of board meeting 11 Dec, 3:37 PM Genpharmasec informs about board meeting 1 Nov, 5:13 PM Genpharmasec to acquire 70% stake in Derren Healthcare 20 Sep, 2:42 PM Genpharmasec informs about AGM 1 Sep, 12:43 PM Genpharmasec incorporates foreign subsidiary 14 Jul, 2:28 PM Genpharmasec informs about incorporation of subsidiary company 14 Jul, 2:16 PM Genpharmasec planning to raise funds 30 May, 3:40 PM Genpharmasec informs about newspaper publication 10 May, 5:39 PM Genpharmasec informs about compliance certificate 18 Apr, 5:16 PM Genpharmasec informs about separate meeting of independent directors 27 Mar, 4:53 PM Genpharmasec - Quaterly Results 10 Feb, 5:37 PM Genpharmasec - Quaterly Results 10 Feb, 5:37 PM Genpharmasec informs about financial results 14 Nov, 5:44 PM Genpharmasec informs about resignation of director 11 Oct, 4:25 PM Genpharmasec informs about resignation of independent director 6 Oct, 4:21 PM Genpharmasec informs about scrutinizers report 3 Oct, 5:00 PM Genpharmasec informs about annual report 6 Sep, 12:55 PM Genpharmasec - Quaterly Results 10 Aug, 4:31 PM Genpharmasec informs about board meeting 18 May, 3:21 PM Genpharmasec - Quaterly Results 14 Feb, 6:07 PM Genpharmasec informs about disclosure 19 Jan, 10:01 AM Generic Pharmasec informs about confirmation certificate 14 Oct, 3:13 PM Generic Pharmasec successfully executes order from Reliance Group 27 Jul, 12:48 PM Generic Pharmasec enters into agreement with Abbott Point of Care 1 Jun, 12:00 PM Generic Pharmasec submits compliance certificate 20 Apr, 5:16 PM Generic Pharmasec informs about board meeting 2 Feb, 4:04 PM

Genpharmasec Stock Price Analysis and Quick Research Report. Is Genpharmasec an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Genpharmasec . 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Genpharmasec has a PE ratio of 110.416666666667 which is high and comparatively overvalued .

  • Share Price: - The current share price of Genpharmasec is Rs 3.18. One can use valuation calculators of ticker to know if Genpharmasec share price is undervalued or overvalued.

  • Return on Assets (ROA): - Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Genpharmasec has ROA of 0.1037 % which is a bad sign for future performance. (higher values are always desirable)

  • Current ratio: - The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Genpharmasec has a Current ratio of 14.8476 .

  • Return on equity: - ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Genpharmasec has a ROE of 0.1156 % .(higher is better)

  • Debt to equity ratio: - It is a good metric to check out the capital structure along with its performance. Genpharmasec has a Debt to Equity ratio of 0.0497 which means that the company has low proportion of debt in its capital.

  • Sales growth: - Genpharmasec has reported revenue growth of 19.1647 % which is fair in relation to its growth and performance. 

  • Operating Margin: - This will tell you about the operational efficiency of the company. The operating margin of Genpharmasec for the current financial year is 0.527532666572395 %.

  • Dividend Yield: - It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Genpharmasec is Rs 0 and the yield is 0 %.

  • Earnings Per Share: - It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Genpharmasec is Rs 0.0288 . The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Genpharmasec in Ticker for free. Also, one can get the intrinsic value of Genpharmasec by using Valuation Calculators, which are available with a Finology ONE subscription. 

Last Updated on:
Brief about Genpharmasec
X